Sector News

AZ’ Lisa Anson elected as ABPI president

December 8, 2016
Life sciences

AstraZeneca UK’s president Lisa Anson is to take over the reigns of President of the Association of the British Pharmaceutical Industry.

Anson, who holds a MBA with distinction from INSEAD in France and a First Class degree in Natural Sciences from Cambridge University, has held a variety of senior management roles at AZ in both the US and the UK, following stints at an American healthcare firm and consultancy KPMG.

She joined the ABPI Board in January 2012, and has been engaged in a number of capacities since, leading on a number of key commercial projects such as implementing the UK’s Pharmaceutical Pricing Regulation Scheme (PPRS), which caps the total spend of branded medicines for the NHS.

Lisa will take over from current president John Kearney, General Manager at Amgen, from the end of April, and her time in the position will be very much focused on representing ABPI members during Brexit, and working with government to develop “a life-science strategy which puts the industry as a key strategic partner in the government’s future economic plans”, the Agency notes.

“During my term as president, our industry will face crucial issues including the UK’s departure from the European Union, ensuring biopharmaceuticals are central to the UK industrial strategy and leveraging a golden period of innovation in new medicines to ensure UK patients benefit,” Anson noted. “The ABPI is at the frontline of protecting and nurturing our relationship with government and the NHS, which will be vital to navigate these important issues.”

“The unanimous decision by the ABPI Board to elect Lisa Anson as President shows the esteem in which she is held,” said ABPI chief executive, Mike Thompson. “As a high profile president of AstraZeneca UK and Ireland her knowledge and experience will be valuable as we head into what is arguably the UK pharmaceutical industry’s most challenging era to date.”

By Selina McKee

Source: Pharma Times

comments closed

Related News

January 29, 2023

Colorcon, Inc. signs Put agreement with intent to acquire controlled atmosphere packaging specialist Airnov Healthcare Packaging

Life sciences

Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.

January 29, 2023

Takeda pledges up to $1.13B for rights to Hutchmed’s cancer drug fruquintinib outside of China

Life sciences

Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.

January 29, 2023

Vir taps Bayer dealmaker Marianne De Backer as its next CEO

Life sciences

On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.

How can we help you?

We're easy to reach